Asymmetry Capital Management L.P. Trims Holdings in Aerie Pharmaceuticals, Inc. (AERI)

Asymmetry Capital Management L.P. reduced its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 47.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,464 shares of the company’s stock after selling 23,336 shares during the period. Aerie Pharmaceuticals makes up 1.6% of Asymmetry Capital Management L.P.’s portfolio, making the stock its 23rd largest holding. Asymmetry Capital Management L.P. owned approximately 0.07% of Aerie Pharmaceuticals worth $1,338,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AERI. Quantbot Technologies LP bought a new stake in Aerie Pharmaceuticals in the 1st quarter valued at $107,000. Ameritas Investment Partners Inc. bought a new stake in Aerie Pharmaceuticals in the 1st quarter valued at $108,000. BNP Paribas Arbitrage SA increased its holdings in Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after acquiring an additional 3,579 shares during the last quarter. BlueCrest Capital Management Ltd bought a new stake in Aerie Pharmaceuticals in the 1st quarter valued at $202,000. Finally, Amalgamated Bank bought a new stake in Aerie Pharmaceuticals in the 2nd quarter valued at $204,000. Institutional investors own 94.64% of the company’s stock.

A number of brokerages have issued reports on AERI. Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Aerie Pharmaceuticals in a report on Sunday, September 17th. Canaccord Genuity set a $65.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 16th. BidaskClub downgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $62.00 price target (up from $56.00) on shares of Aerie Pharmaceuticals in a report on Thursday, July 20th. Finally, JMP Securities set a $68.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $67.46.

Shares of Aerie Pharmaceuticals, Inc. (AERI) traded down 0.39% during trading on Thursday, hitting $64.05. 655,084 shares of the company’s stock were exchanged. The company’s market cap is $2.33 billion. The company has a 50-day moving average of $54.84 and a 200-day moving average of $50.60. Aerie Pharmaceuticals, Inc. has a 12-month low of $32.05 and a 12-month high of $65.89.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.02. On average, equities analysts expect that Aerie Pharmaceuticals, Inc. will post ($2.59) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Asymmetry Capital Management L.P. Trims Holdings in Aerie Pharmaceuticals, Inc. (AERI)” was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/10/12/asymmetry-capital-management-l-p-trims-holdings-in-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply